AREV Life Sciences Global Corp
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AREVF research report →
Price Chart
About the company
AREV Life Sciences Global Corp. , established in Coquitlam, Canada in 2005, operates as an integrated life science discovery firm, focusing on the development and sale of functional ingredients throughout Canada. Its diverse product line includes various CBD-infused items like the anti-viral supplements Canna-Mulsion and NaturVax, NaturRelax for natural sleep support, and Natur Relief, designed for anti-inflammatory and pain relief.
- CEO
- Michael C. Withrow
- IPO
- 2019
- Employees
- 19,534
- HQ
- Coquitlam, BC, CA
Get TickerSpark's AI analysis on AREVF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $15.88K
- P/E
- -1.87
- PEG
- -0.03
- P/S
- 57.79
- P/B
- -2.84
- EV/EBITDA
- -2.18
- Div Yield
- 0.00%
- Gross Margin
- -155.72%
- Op Margin
- -2839.86%
- Net Margin
- -2940.37%
- ROE
- 276.09%
- ROIC
- 150.98%
Latest fiscal year · YoY change
- Revenue
- $49.11K-80.7%
- Gross Profit
- $29.14K-84.3%
- Op Income
- $-1,388,788
- Net Income
- $-1,444,106-45.8%
- EPS
- $-0.05-33.0%
- OCF Growth
- +80.7%
- FCF Growth
- +75.3%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 4.94
- RSI (14)
- 0
- Avg Volume
- 9.56K
No earnings-call transcripts are available for AREVF yet.
- Free Float
- 53.0%
- Shares Outstanding
- 31.76M
- Float Shares
- 16.83M
Our AREVF coverage
Recent articles, reports, and earnings notes.
No research on AREVF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AREVF report →AREV Signs Definitive Collaborative Development Agreement with Voynich Biosciences and Invites Richard van Breemen PhD to SAB
globenewswire.com · Sep 7
AREV Announces Brian Cameron as Chief Financial Officer
globenewswire.com · Sep 2
AREV Signs Definitive Collaborative Development Agreement with Voynich Biosciences and Invites Richard van Breemen PhD to SAB
globenewswire.com · Jul 29
Data Presented at the 11th IAS Conference on HIV Science Supports AREV's Development of SUS-TAINN™, a Ready-to-Use Therapeutic Food to Treat Global Malnutrition and Starvation
globenewswire.com · Jul 22
AREV Annual and Special General Meeting Results
globenewswire.com · Jul 20
AREV Expands Operations to Rochester New York Establishing Wholly Owned U.S. Subsidiary, AREV Life Sciences, Inc.
globenewswire.com · Jul 6
AREV Completes Land Survey and Soil Analysis for Cultivation of Mushrooms and Moringa and Prepares for Mass Production of Plant-Based Proteins For Use in Its Ready-To-Use Therapeutic Foods
globenewswire.com · Jun 16
AREV CEO Michael Withrow Buys 900,000 Shares of Company Stock
globenewswire.com · Jun 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.